These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17044191)

  • 1. The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusion.
    Li Q; Bavikatty N; Michael CW
    Semin Diagn Pathol; 2006 Feb; 23(1):15-9. PubMed ID: 17044191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.
    Pu RT; Pang Y; Michael CW
    Diagn Cytopathol; 2008 Jan; 36(1):20-5. PubMed ID: 18064689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
    Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
    Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Accuracy of a Limited Immuno-panel of Calretinin and Ber-EP4 for Diagnosis of Malignant Effusions.
    Khurram N; Anis T; Yusuf NW
    J Coll Physicians Surg Pak; 2019 Jan; 29(1):33-36. PubMed ID: 30630566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions.
    Chhieng DC; Yee H; Schaefer D; Cangiarella JF; Jagirdar J; Chiriboga LA; Jagirdar J; Chiriboga LA; Cohen JM
    Cancer; 2000 Jun; 90(3):194-200. PubMed ID: 10896333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY; Li GD; Liu WP; Xie B; Jiang YH
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
    Shield PW; Koivurinne K
    Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
    Pan CC; Chen PC; Chou TY; Chiang H
    Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
    Ordóñez NG
    Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma.
    Leers MP; Aarts MM; Theunissen PH
    Histopathology; 1998 Mar; 32(3):209-16. PubMed ID: 9568505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of malignant cells in serous effusions using a panel of monoclonal antibodies Ber-EP4, MCA-b-12 and EMA.
    Stoop JA; Hendriks JG; Berends D
    Cytopathology; 1992; 3(5):297-302. PubMed ID: 1288655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
    Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
    Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis.
    Carella R; Deleonardi G; D'Errico A; Salerno A; Egarter-Vigl E; Seebacher C; Donazzan G; Grigioni WF
    Am J Surg Pathol; 2001 Jan; 25(1):43-50. PubMed ID: 11145250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions.
    Delahaye M; van der Ham F; van der Kwast TH
    Diagn Cytopathol; 1997 Aug; 17(2):115-20. PubMed ID: 9258618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
    Hyun TS; Barnes M; Tabatabai ZL
    Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens.
    Kim MJ; Shin HC; Shin KC; Ro JY
    Ann Diagn Pathol; 2013 Feb; 17(1):85-90. PubMed ID: 23040737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.